Archives
-
Red Blood Cell Lysis Buffer in Bone Research
2026-09-28
See how Red Blood Cell Lysis Buffer can support blood-based assays in bone research without confusing those workflows with osteoblast experiments. We connect selective erythrocyte removal to the interpretation and limits of evidence on RUNX2 and AMPK.
-
Fluorouracil Workflows for Cancer Research
2026-09-27
Build reproducible 5-Fluorouracil experiments around a defined thymidylate-synthase mechanism, matched vehicle controls, and orthogonal readouts. A practical bridge to gastric cancer stem-cell biology helps researchers ask whether treatment changes viability and stem-like behavior—without assuming the reference study tested Fluorouracil.
-
Tankyrase Inhibition Suppresses HCC via Hippo Signaling
2026-09-26
Jia et al. found that the tankyrase inhibitors XAV-939 and G007-LK reduced growth across human hepatocellular carcinoma cell models while lowering YAP activity and increasing the YAP-negative regulators AMOTL1 and AMOTL2. The results connect tankyrase inhibition to Hippo pathway control and suggest a mechanism worth testing alongside other targeted approaches, while remaining preclinical cell-based evidence.
-
Sodium chloride B7288: Buffer Preparation and QC
2026-09-25
Sodium chloride B7288 provides a defined source of NaCl for adjusting ionic strength and osmotic balance in aqueous buffers, assays, and cell culture media formulations. Use it when a formulation calls for sodium chloride, but do not treat it as a pH buffer, a DMSO- or ethanol-soluble reagent, or a sterility-qualified material.
-
MG-132 Workflows for Proteostasis and Apoptosis
2026-09-25
Use MG-132 to test whether proteasome-dependent protein turnover contributes to endothelial injury, apoptosis, or cell-cycle changes. This workflow pairs short, titrated inhibitor exposures with ubiquitination and protein-stability readouts, helping distinguish a mechanistic probe from a nonspecific cytotoxic treatment.
-
Primary Antibody Dilution Buffer for PCNSL Assays
2026-09-24
Translate single-cell findings on fructose metabolism in primary CNS lymphoma into carefully controlled protein-localization experiments. This practical guide explains how to use an antibody dilution buffer in tissue and cell workflows, with optimization steps that separate product information from assay-specific recommendations.
-
Annexin V-Cy5/DAPI: Reading Leukemia Cell Fate
2026-09-24
Learn how the Annexin V-Cy5/DAPI Apoptosis Kit can help interpret treatment-induced cell death in Ph+ ALL. This article connects phosphatidylserine and membrane-integrity signals to pathway evidence, assay timing, and the limits of endpoint interpretation.
-
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-09-23
Single-cell multi-omic profiling links the nutrient-poor, hypoxic environment of primary CNS lymphoma to SLC2A5-mediated fructose metabolism in tumor cells and tumor-supportive macrophages. Functional experiments identify SLC2A5 as a preclinical metabolic vulnerability, while leaving clinical efficacy and the best strategy for targeting this pathway unresolved.
-
Trelagliptin, RUNX2, and Osteoblastic Differentiation
2026-09-23
The reference study identifies a potential bone-forming action of the DPP-4 inhibitor trelagliptin in MC3T3-E1 cells, linking enhanced mineralization to RUNX2 and AMPK signaling. Its findings provide a mechanistic basis for further osteoporosis research, while remaining preclinical and limited to a cellular model.
-
Cefodizime for Resistance-Aware Research
2026-09-22
Cefodizime is a third-generation cephalosporin antibiotic with a useful profile for mechanism-focused microbiology and resistance-aware assay design. This article connects its PBP pharmacology with hospital surveillance data to define practical, evidence-conscious research workflows.
-
Canagliflozin Hemihydrate: SGLT2 Research Guide
2026-09-22
Canagliflozin hemihydrate is a research-grade small-molecule SGLT2 inhibitor for glucose metabolism research and renal glucose reabsorption studies. A 2025 drug-sensitized yeast study found no evidence that canagliflozin inhibited TOR in that model, defining an important mechanistic boundary.
-
CDC20–GSDME Pyroptosis in Prostate Cancer
2026-09-21
Wu et al. identify CDC20 as an upstream suppressor of GSDME-mediated pyroptosis in prostate cancer, linking ubiquitin-dependent protein turnover to immune visibility. Their genetic, biochemical, transcriptomic, and mouse-model data indicate that CDC20 inhibition can promote CD8+ T-cell infiltration and improve anti-PD-1 responses, although the findings remain preclinical.
-
Sulfamonomethoxine Toxicity in Aquatic Organisms
2026-09-21
Huang and colleagues assessed sulfamonomethoxine toxicity across algae, cladocerans, and medaka, integrating acute and chronic endpoints across aquatic trophic levels. The study found that microalgae were more sensitive than cladocerans in the reported assays, highlighting the value of multi-organism testing when evaluating aquaculture antibiotic residues.
-
Chloroquine Diphosphate: Autophagy Assay Workflows
2026-09-20
Build more interpretable autophagy, chemotherapy sensitization, and AML-focused experiments with an aqueous, flux-aware workflow for Chloroquine Diphosphate. The guide also shows how to use the compound as a mechanistic comparator when studying ferroptosis and ACSL4-linked lipid remodeling without overstating evidence.
-
Amyloid Beta-peptide (25-35): Research Guide
2026-09-19
Amyloid Beta-peptide (25-35), also called Aβ25-35, is a synthetic human amyloid beta fragment used as a controlled model of amyloid-induced neuronal injury. It supports cell-based studies of oxidative stress, mitochondrial dysfunction, amyloid aggregation, microglial activation, and neuroprotective strategies.